Paragon Associates & Paragon Associates II Joint Venture’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-46,646	Closed	-$4.69M	–	18
2021 Q3	$4.69M	Sell	46,646 -21,454	-32%	-$2.51M	5.31%	9
2021 Q2	$9.64M	Sell	68,100 -31,900	-32%	-$3.6M	12.82%	2
2021 Q1	$9.97M	Sell	100,000 -40,000	-29%	-$4.67M	15.2%	3
2020 Q4	$17.3M	Sell	140,000 -10,000	-7%	-$1.31M	26.61%	1
2020 Q3	$14.6M	Sell	150,000 -51,000	-25%	-$6.37M	19.62%	3
2020 Q2	$31.4M	Sell	201,000 -2,500	-1%	-$380K	34.45%	1
2020 Q1	$29.4M	Sell	203,500 -18,500	-8%	-$3.57M	31.55%	1
2019 Q4	$45.4M	Sell	222,000 -23,000	-9%	-$4.2M	25.5%	1
2019 Q3	$19.7M	Hold	245,000	–	–	15.18%	1
2019 Q2	$23.1M	Hold	245,000	–	–	17.8%	1
2019 Q1	$20.9M	Hold	245,000	–	–	19.75%	1
2018 Q4	$13.7M	Buy	245,000 +5,000	+2%	+$305K	18.25%	1
2018 Q3	$19.6M	Sell	240,000 -10,000	-4%	-$705K	22.37%	1
2018 Q2	$8.74M	Hold	250,000	–	–	11.36%	2
2018 Q1	$5.13M	Hold	250,000	–	–	7.47%	5
2017 Q4	$7.08M	Hold	250,000	–	–	5.89%	9
2017 Q3	$7.78M	Hold	250,000	–	–	6.64%	7
2017 Q2	$7.91M	Hold	250,000	–	–	8.98%	6
2017 Q1	$5.66M	Hold	250,000	–	–	6.09%	7
2016 Q4	$5.46M	Buy	250,000 +100,000	+67%	+$2.53M	7.26%	5
2016 Q3	$3.95M	Hold	150,000	–	–	4.57%	10
2016 Q2	$2.96M	Buy	+150,000	New	+$2.92M	2.9%	11

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's RETA Position: Q4 2021 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 46,646 shares — an estimated $4.69M sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in RETA in Q2 2016 and held it in 22 quarters. The position peaked at $45.4M in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Paragon Associates & Paragon Associates II Joint Venture reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Paragon Associates & Paragon Associates II Joint Venture sold 46,646 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $4.69M.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 22 quarters.
Paragon Associates & Paragon Associates II Joint Venture's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $45.4M in Q4 2019.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q4 2021, filed 14 Feb 2022.